Our cities

Arequipa

Peru

Building on Peru’s recently adopted cancer law, Arequipa has joined C/Can to generate learnings and best practices that can be replicated and scaled across the country. Cancer is currently the second most common cause of death nationwide, and Arequipa is striving to light a path towards a new, multi-disciplinary approach to tackling the disease.

  • Country

  • Joined C/CAN

    January 2022

Arequipa-Peru-City-Cancer-Challenge
Why it matters
  • 176.3
    Cancer incidence rate (per 100,000)
  • 1.3 M
    Arequipa population
  • 85.5
    Cancer mortality rate (per 100,000)

Discover our projects

Local cancer care experts are leading projects designed to respond to the city’s challenges and enhance its capacity to address patient needs.

View all
Cross City Projects

Gender-responsive health systems for cancer care

To contribute to the organisation’s gender equity strategy, C/Can has put together a working group to generate recommendations on how to build gender-responsive health systems.

Cross City Projects

Seed grants for cancer health system research in C/Can cities

Providing seed funding to support researchers in C/Can’s network of cities, who are investigating health system research projects through an implementation science lens.

Cross City Projects

Implementation science masterclass

Needs and challenges in Arequipa

A multidisciplinary technical committee of local experts and institutions is currently undertaking an analysis of the state of cancer care in the city and identifying essential priorities.

Victor Palacios

Peru’s health sector is implementing structural changes to fight cancer in an organised and integrated manner, so this MoU is a propitious moment to strengthen our work in reducing the burden of this disease.

Victor Palacios
Executive Director of Cancer Prevention and Control at the Peruvian Ministry of Health

Stories from Arequipa

View all
Cookie notice

This website uses its own and third-party cookies to improve the browsing experience. Read the Cookies Policy.